Sowell Financial Services LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 8.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,229 shares of the company’s stock after buying an additional 608 shares during the period. Sowell Financial Services LLC’s holdings in Eli Lilly and Company were worth $9,522,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently bought and sold shares of LLY. Marshall & Sterling Wealth Advisors Inc. increased its position in shares of Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in Eli Lilly and Company in the 1st quarter valued at $42,000. Caitlin John LLC acquired a new position in Eli Lilly and Company in the 2nd quarter worth $64,000. IMG Wealth Management Inc. boosted its stake in Eli Lilly and Company by 500.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock worth $72,000 after purchasing an additional 50 shares during the period. Finally, Whipplewood Advisors LLC increased its holdings in Eli Lilly and Company by 213.8% during the 1st quarter. Whipplewood Advisors LLC now owns 91 shares of the company’s stock worth $84,000 after purchasing an additional 62 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.
Analysts Set New Price Targets
Several analysts have issued reports on LLY shares. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $1,500.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 12th. Leerink Partners boosted their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a report on Wednesday, October 21st. Finally, UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,320.25.
Check Out Our Latest Research Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
LLY stock opened at $1,372.01 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market cap of $1.29 trillion, a price-to-earnings ratio of 46.04, a PEG ratio of 1.73 and a beta of 0.46. The company’s fifty day simple moving average is $1,194.34 and its 200 day simple moving average is $1,090.89. Eli Lilly and Company has a 12-month low of $812.25 and a 12-month high of $1,408.38.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.68 by $1.80. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same period last year, the company posted $7.02 earnings per share. The business’s quarterly revenue was up 38.6% on a year-over-year basis. On average, analysts expect that Eli Lilly and Company will post 33.22 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.
Trending Headlines about Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Strong earnings and sales beat estimates. Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the roughly $5.68 analyst consensus. Reported EPS was $7.22, up from $6.21 a year earlier. Eli Lilly earnings report
- Positive Sentiment: Demand for GLP-1 drugs continues to accelerate. Mounjaro sales increased 65% to $10.7 billion, while Zepbound revenue climbed 49% to $5.35 billion. The performance reinforced expectations that Lilly can continue gaining share in the rapidly expanding diabetes and obesity markets. Eli Lilly stock jumps on Mounjaro and Zepbound earnings
- Positive Sentiment: Management sharply increased its outlook. Lilly raised 2026 revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The company also highlighted regulatory progress, including Mounjaro’s cardiovascular-risk indication and approval of once-weekly insulin Onswik. Eli Lilly raises revenue outlook
- Positive Sentiment: Pipeline momentum added to investor enthusiasm. Phase 3 data showed experimental retatrutide produced greater A1C reductions and more than double the weight loss of Ozempic 2 mg in adults with type 2 diabetes, strengthening Lilly’s competitive position against Novo Nordisk. Retatrutide trial results
- Neutral Sentiment: Investors should monitor the quality and durability of growth. Realized prices declined about 15%, although a 53% volume increase more than offset the pressure. Approximately $900 million of quarterly benefits came from Jardiance milestones and rebate adjustments, neither of which is expected to recur fully.
- Negative Sentiment: One-time deal-related charges and access concerns remain risks. Lilly recorded about $4.2 billion in acquired in-process R&D charges, while reports also noted a Foundayo sales miss and potential employer concerns about covering costly weight-loss drugs. These factors could pressure margins or slow future demand. Eli Lilly pricing and earnings reaction
Insider Activity
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.
The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
